+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
IPCALAB

Ipca Laboratories Share Price

₹1,919.20 +19.3 (1.02%)
53.34% Gain from 52W Low

13 Oct, 2026 3:58 PM (IST)

Ipca Laboratories live price: ₹1,919.20. It opened at ₹1,909 vs previous close ₹1,900; intraday high/low: ₹1,940/₹1,861. The 50 & 200 DMA stand at ₹1,901.10/₹1,697.30.

Ipca Laboratories Performance

  • Today's Low
  • ₹1,861
  • Today's High
  • ₹1,940
  • 52 Week Low
  • ₹1,252
  • 52 Week High
  • ₹2,038
  • Open Price₹1,909
  • Previous Close₹1,900
  • Volume349,659
  • 50 DMA₹1,901.10
  • 100 DMA₹1,815.20
  • 200 DMA₹1,697.30

Ipca Laboratories Chart

Investment Returns

  • Over 1 Month -2.5%
  • Over 3 Month + 7.34%
  • Over 6 Month + 31.8%
  • Over 1 Year + 43.81%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.2
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 48,691
  • P/B Ratio
  • 5.7
  • Average True Range
  • 55.5
  • EPS
  • 51.6
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -1.4
  • RSI
  • 46.62
  • MFI
  • 22.35

Latest Stock News Updates

Ipca Laboratories Ltd - 524494 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

The Company has enclosed herewith certificate recived from RTA under reg 74 5 for the quarter ended 30.09.2026.

Ipca Laboratories Ltd - 524494 - Closure of Trading Window

Closure of Trading Window

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Transcript of Conference Call

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,919.20
+ 19.3 (1.02%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹1,938.40
  • 50 Day
  • ₹1,901.10
  • 100 Day
  • ₹1,815.20
  • 200 Day
  • ₹1,697.30

Resistance and Support

1906.87 Pivot Speed
  • R3 2,030.90
  • R2 1,985.50
  • R1 1,952.30
  • S1 1,873.70
  • S2 1,828.30
  • S3 1,795.10

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-13 Quarterly Results
2026-05-29 Audited Results & Dividend
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
Date Purpose Remarks
2026-08-07 FINAL Rs.6.00 per share(600%)Dividend
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Stock split from Rs. 2/- to Re. 1/-.
2010-03-23 Split

Ipca Laboratories Shareholding Pattern

44.72%
31.15%
10.72%
7.19%
6.21%

About Ipca Laboratories

Ipca Laboratories is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical ingredients (APIs).(Source : AR-PDF:202603-01 Pg No: 114) View More
  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Executive Director.(Professional.),Managing Director,Chief Financial Officer,Non Promoter
  • A K Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,919 As on 13 October, 2026 | 17:49

The Market Cap of Ipca Laboratories is ₹48690.9 Cr As on 13 October, 2026 | 17:49

The P/E ratio of Ipca Laboratories is 37.2 As on 13 October, 2026 | 17:49

The PB ratio of Ipca Laboratories is 5.7 As on 13 October, 2026 | 17:49

The 52 week High & Low of Ipca Laboratories is ₹2038/₹1251.6 respectively As on 13 October, 2026 | 17:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23